The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data.

The incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.